Details
Stereochemistry | EPIMERIC |
Molecular Formula | C17H20N2O5S |
Molecular Weight | 364.416 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C)OC3=CC=CC=C3)C(O)=O
InChI
InChIKey=NONJJLVGHLVQQM-JHXYUMNGSA-N
InChI=1S/C17H20N2O5S/c1-9(24-10-7-5-4-6-8-10)13(20)18-11-14(21)19-12(16(22)23)17(2,3)25-15(11)19/h4-9,11-12,15H,1-3H3,(H,18,20)(H,22,23)/t9?,11-,12+,15-/m1/s1
Molecular Formula | C17H20N2O5S |
Molecular Weight | 364.416 |
Charge | 0 |
Count |
|
Stereochemistry | EPIMERIC |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://db.cbg-meb.nl/IB-teksten/h09101.pdfCurator's Comment: description was created based on several sources, including:
doi: 10.1136/bmj.2.5197.534
Sources: http://db.cbg-meb.nl/IB-teksten/h09101.pdf
Curator's Comment: description was created based on several sources, including:
doi: 10.1136/bmj.2.5197.534
Pheneticillin (phenoxyethylpenicillin) is an oral penicillin used for the treatment of upper respiratory tract infections; lower respiratory tract infections; skin and soft tissue infections. Pheneticillin inhibits the synthesis of the cell wall by inhibiting the penicillin binding proteins (PBPs) function. It is well absorbed from the gastrointestinal tract. It reaches the pleural and peritoneal cavities but doesn’t cross the blood-brain barrier. Diarrhea has sometimes occurred with therapeutic doses in man.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Broxil Approved UseIt is indicated for the treatment of infections, caused by susceptible microorganisms. In particular streptococcal infections, such as: upper respiratory tract infections (for example, pharyngitis); lower respiratory tract infections (for example, pneumonia); skin and soft tissue infections (for example, abscesses or impetigo). Launch Date1965 |
|||
Curative | Broxil Approved UseIt is indicated for the treatment of infections, caused by susceptible microorganisms. In particular streptococcal infections, such as: upper respiratory tract infections (for example, pharyngitis); lower respiratory tract infections (for example, pneumonia); skin and soft tissue infections (for example, abscesses or impetigo). Launch Date1965 |
|||
Curative | Broxil Approved UseIt is indicated for the treatment of infections, caused by susceptible microorganisms. In particular streptococcal infections, such as: upper respiratory tract infections (for example, pharyngitis); lower respiratory tract infections (for example, pneumonia); skin and soft tissue infections (for example, abscesses or impetigo). Launch Date1965 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3924086/ |
500 mg 1 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
PHENETICILLIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
29.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3924086/ |
500 mg 1 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
PHENETICILLIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
63 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3924086/ |
500 mg 1 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
PHENETICILLIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3924086/ |
500 mg 1 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
PHENETICILLIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg 4 times / day multiple, oral Highest studied dose Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: |
unhealthy, 54 (19–71) n = 120 Health Status: unhealthy Condition: Infection Age Group: 54 (19–71) Sex: M+F Population Size: 120 Sources: |
|
1 g 1 times / day single, oral Highest studied dose Dose: 1 g, 1 times / day Route: oral Route: single Dose: 1 g, 1 times / day Sources: |
unhealthy, 58.3±15.4(19–90) n = 84 Health Status: unhealthy Condition: Infection Age Group: 58.3±15.4(19–90) Sex: M+F Population Size: 84 Sources: |
|
250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: Infection Age Group: adult Sex: M+F Population Size: 437 Sources: |
Disc. AE: Dermatitis, Throbbing headache... AEs leading to discontinuation/dose reduction: Dermatitis Sources: Throbbing headache Hypersensitivity reaction |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dermatitis | Disc. AE | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: Infection Age Group: adult Sex: M+F Population Size: 437 Sources: |
Hypersensitivity reaction | Disc. AE | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: Infection Age Group: adult Sex: M+F Population Size: 437 Sources: |
Throbbing headache | Disc. AE | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: Infection Age Group: adult Sex: M+F Population Size: 437 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Identification of penicillin allergenic determinants that bind IgE antibodies in the sera of subjects with penicillin allergy. | 1990 Nov |
|
A prospective placebo-controlled double-blind trial of antibiotic prophylaxis in intraoral bone grafting procedures: a pilot study. | 2003 Dec |
|
The history of penicillin from discovery to the drive to production. | 2004 Sep |
|
Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. | 2008 Feb |
|
A complete library of amino acid alterations at R306 in Streptomyces clavuligerus deacetoxycephalosporin C synthase demonstrates its structural role in the ring-expansion activity. | 2008 Feb 15 |
|
Complete genome sequence and comparative metabolic profiling of the prototypical enteroaggregative Escherichia coli strain 042. | 2010 Jan 20 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://db.cbg-meb.nl/Bijsluiters/h04959.pdf
250 mg every 8 hours
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3924086
The MIC against S. aureus of Pheneticillin in broth was 0.031 mg/l.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:19:57 GMT 2023
by
admin
on
Fri Dec 15 18:19:57 GMT 2023
|
Record UNII |
EFA30X554H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J01CE05
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
||
|
WHO-VATC |
QJ01CE05
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
147-55-7
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
100000082232
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
52427
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
PHENETICILLIN
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
2124
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
272833
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
EFA30X554H
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
DB13337
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
SUB09759MIG
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
C170316
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
117548
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL1614637
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
33277
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | RxNorm | ||
|
205-691-4
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
1011
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
DTXSID6023448
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
C100209
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |